ImpediMed picks Australian site for L-Dex trial
ImpediMed (ASX:IPD) has selected the Macquarie University Cancer Institute (MCI) as the Australian site for a post-approval clinical study of its L-Dex lymphodoema detection device.
The clinical trial will involve three sites in the US and one in Australia. It will aim to establish the clinical utility of L-Dex for the early detection of lymphodoema.
Interim data from the trial will be used to help ImpediMed seek coverage from private US health insurers and drive market adoption of the product.
The principal investigators for the Australian arm of the trial will be MCI Director and Professor of Breast Oncology Professor John Boyages and veteran occupational therapist Louise Koelmeyer.
Boyages has 30 years’ experience in the diagnosis and treatment of breast cancer, and was the founding director of the Westmead Breast Cancer Institute.
Koelmeyer has 23 years of clinical experience, specialising in breast cancer rehabilitation and lymphoedema management. She is an active member on several Australasian Lymphology Association committees and oversees the coordination of MCI’s Survivorship programs.
“We are very excited to add Macquarie Cancer Institute, home to some of the world’s most pre-eminent researchers - such as Professor Boyages and Louise Koelmeyer - to this trial,” ImpediMed CEO Richard Carreon said.
ImpediMed (ASX:IPD) shares were trading 3.64% lower at $0.265 as of around 1 pm on Wednesday.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
